https://scholars.lib.ntu.edu.tw/handle/123456789/551242
標題: | Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer | 作者: | Chua D.T.T. Yiu H.H.-Y. Seetalarom K. Ng A.W.-Y. Kurnianda J. Shotelersuk K. Krishnan G. RUEY-LONG HONG Yang M.-H. Wang C.-H. Sze W.-K. Ng W.-T. |
關鍵字: | capecitabine; cisplatin; distant metastases; nasopharyngeal cancer; palliative chemotherapy | 公開日期: | 2012 | 卷: | 34 | 期: | 9 | 起(迄)頁: | 1225-1230 | 來源出版物: | Head and Neck | 摘要: | Background Capecitabine is an oral fluoropyrimidine with single-agent activity in metastatic nasopharyngeal carcinoma (NPC). This multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus cisplatin as a first-line treatment for metastatic NPC. Methods Patients with metastatic NPC received cisplatin 100 mg/m2 day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 6-8 cycles. The primary endpoint was overall response rate. Results Forty-four patients were enrolled; 39 patients were evaluable for efficacy. The overall response rate was 53.8% (95% confidence interval [CI], 37%-70%), including 1 complete response. Median time to tumor progression was 7.3 months (95% CI, 5.6-9.9 months) and median overall survival was 28.0 months (95% CI, 14.5 months-not reached). Common grade 3/4 adverse events were neutropenia (50%), vomiting (11%), thrombocytopenia (9%), and nausea (7%). Conclusions Capecitabine plus cisplatin is an active first-line combination in metastatic NPC that requires a short hospital stay. ? 2011 Wiley Periodicals, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864966763&doi=10.1002%2fhed.21884&partnerID=40&md5=5fd12030cdd7df100ba1da1d234bf39b https://scholars.lib.ntu.edu.tw/handle/123456789/551242 |
ISSN: | 1043-3074 | DOI: | 10.1002/hed.21884 | SDG/關鍵字: | capecitabine; carboplatin; cisplatin; cyclophosphamide; fluorouracil; gefitinib; gemcitabine; paclitaxel; adult; aged; anemia; anorexia; article; bone metastasis; cancer chemotherapy; cancer patient; cancer survival; cancer therapy; clinical article; constipation; diarrhea; drug efficacy; drug safety; drug tolerability; febrile neutropenia; female; hand foot syndrome; human; kidney disease; male; mucosa inflammation; multicenter study; multiple cycle treatment; nasopharynx cancer; nausea; neutropenia; open study; overall survival; priority journal; progression free survival; quality of life; sepsis; thrombocytopenia; tinnitus; treatment response; tumor growth; vomiting; Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Quality of Life; Survival Analysis; Treatment Outcome; Young Adult |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。